Editor's Corner

With just a little under two weeks to go, we're closing in on 200 registrants for the FierceBiotech webinar on October 27. If you have time available for the 2pm ET event with venture capitalists Steven Burrill, Sherrill Neff and Scott Minnick, along with Ernst & Young's Gil Forer, please make plans to join us. We'll be covering the key issues facing biotech companies that will be looking to raise funds in 2006. So if you're planning to raise a new round, or advise anyone who is, it should be well worth your time. You also can't beat the price. There's no charge to listen in. - John Carroll

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.